PBH

Business Context and Reporting Period

Company: Prestige Brands Holdings, Inc. (Prestige)

Filing Type: Form 10-K (Annual Report)

Reporting Period: Fiscal year ended March 31, 2005

Business Overview: Prestige markets well-recognized, brand-name over-the-counter (OTC) drugs, household cleaning, and personal care products. The company operates a low-cost model by outsourcing manufacturing and logistics to third-party providers while focusing internal resources on marketing, sales, and product development. Major brands include Chloraseptic, Clear Eyes, Compound W, Comet, and Cutex.

Key Events: In February 2005, the company completed an Initial Public Offering (IPO) raising $448.0 million (net proceeds of $416.8 million). Proceeds were used to repay $184.0 million in debt, redeem preferred units, and repurchase common stock held by private equity sponsors.

Key Financial Metrics (Fiscal Year 2005)

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 245.0% to $303.3 million from $87.9 million in fiscal 2004. This surge was primarily driven by the acquisitions of Spic and Span, Bonita Bay (adding Chloraseptic, Comet, Clear Eyes, Murine), and Vetco (adding Little Remedies). On a pro forma basis, sales grew 8.6%.
• Profitability: Net income rose to $13.5 million from $4.2 million in fiscal 2004. However, gross margin percentage declined from 58.7% to 53.4%, largely due to the inclusion of lower-margin household cleaning brands and inventory step-up charges related to acquisitions.
• Interest Expense: Net interest expense increased 351.5% to $44.7 million due to higher indebtedness levels incurred to finance acquisitions prior to the IPO.
• Debt Extinguishment: A one-time loss of $26.9 million was recorded in fiscal 2005 related to the retirement of debt and write-off of deferred financing costs associated with the IPO.

Guidance, Outlook, and Risks

Management Commentary & Strategy:

• Growth Drivers: Focus on advertising investment, new product introductions (e.g., Compound W Freeze Off, Clear Eyes for Dry Eyes), and expanding distribution into dollar stores and international markets.
• Acquisitions: The company intends to pursue strategic add-on acquisitions to enhance its portfolio, leveraging its strong cash flow.
• Operational Efficiency: Continued reliance on third-party manufacturers to maintain a variable cost structure and minimize capital expenditures.

Risks and Contingencies:

• Customer Concentration: The top five customers accounted for 43% of gross sales, with Wal-Mart alone representing approximately 25%. Loss of a major customer could materially impact results.
• Third-Party Dependence: All manufacturing is outsourced. Approximately 29% of gross sales come from products without long-term manufacturing contracts, creating supply chain risks.
• Debt Covenants: The company carries significant debt ($495.4 million) and must maintain specific leverage and interest coverage ratios. Failure to comply could trigger cross-default provisions.
• Legal Proceedings: Pending appeals regarding trade dress infringement (Theodosakis v. Walgreens) and a class action lawsuit regarding pediatric cough products (Dawn Thompson v. Wyeth).

Investor Verification Checklist

• Debt Service Capacity: Verify the company's ability to meet interest coverage and leverage covenants given the $495 million debt load and variable interest rates.
• Customer Concentration: Monitor sales trends with Wal-Mart and other top retailers to assess vulnerability to contract changes or delisting.
• Supply Chain Stability: Review the status of manufacturing agreements, particularly for the 29% of products lacking long-term contracts.
• Acquisition Integration: Assess whether the anticipated cost synergies and revenue growth from recent acquisitions (Bonita Bay, Vetco) are being realized.
• Legal Exposure: Track the outcome of the pending trade dress appeal and the pediatric cough product class action.